REFERENCES
1. Rastogi A. Changing role of histopathology in the diagnosis and management of hepatocellular carcinoma. World J Gastroenterol 2018;24:4000-13.
2. Gaddikeri S, McNeeley MF, Wang CL, Bhargava P, Dighe MK, et al. Hepatocellular carcinoma in the noncirrhotic liver. Am J Roentgenol 2014;203:W34-47.
4. Wörns MA, Bosslet T, Victor A, Koch S, Hoppe-Lotichius M, et al. Prognostic factors and outcomes of patients with hepatocellular carcinoma in non-cirrhotic liver. Scand J Gastroenterol 2012;47:718-28.
5. Schütte K, Kipper M, Kahl S, Bornschein J, Götze T, et al. Clinical characteristics and time trends in etiology of hepatocellular cancer in Germany. Digestion 2013;87:147-59.
6. Trevisani F, Frigerio M, Santi V, Grignaschi A, Bernardi M. Hepatocellular carcinoma in non-cirrhotic liver: a reappraisal. Dig Liver Dis 2010;42:341-7.
7. Zhang Y, Wang C, Xu H, Xiao P, Gao Y. Hepatocellular carcinoma in the noncirrhotic liver: a literature review. Eur J Gastroenterol Hepatol 2019;31:743-8.
8. Schütte K, Schulz C, Poranzke J, Antweiler K, Bornschein J, et al. Characterization and prognosis of patients with hepatocellular carcinoma (HCC) in the non-cirrhotic liver. BMC Gastroenterol 2014;14:117.
9. Lafitte M, Laurent V, Soyer P, Ayav A, Balaj C, et al. MDCT features of hepatocellular carcinoma (HCC) in non-cirrhotic liver. Diagn Interv Imaging 2016;97:355-60.
10. Di Martino M, Saba L, Bosco S, Rossi M, Miles KA, et al. Hepatocellular carcinoma (HCC) in non-cirrhotic liver: clinical, radiological and pathological findings. Eur Radiol 2014;24:1446-54.
11. Desai A, Sandhu S, Lai JP, Sandhu DS. Hepatocellular carcinoma in non-cirrhotic liver: a comprehensive review. World J Hepatol 2019;11:1-18.
12. Nzeako UC, Goodman ZD, Ishak KG. Hepatocellular carcinoma in cirrhotic and noncirrhotic livers. A clinico-histopathologic study of 804 North American patients. Am J Clin Pathol 1996;105:65-75.
13. Adam R, Bismuth H, Castaing D, Waechter F, Navarro F, et al. Repeat hepatectomy for colorectal liver metastases. Ann Surg 1997;225:51-60. discussion 60-2
14. Hadjittofi C, Athanasopoulos PG, Koti RS, Konstantinidou SK, Davidson BR. Long-term survival with repeated resections of recurrent hepatocellular carcinoma in a non-cirrhotic liver: case report and brief review of the literature. Ann Transl Med 2016;4:112.
15. el-Refaie A, Savage K, Bhattacharya S, Khakoo S, Harrisson TJ, et al. HCV-associated hepatocellular carcinoma without cirrhosis. J Hepatol 1996;24:277-85.
16. Ray RB, Meyer K, Ray R. Hepatitis C virus core protein promotes immortalization of primary human hepatocytes. Virology 2000;271:197-204.
17. Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 2006;6:674-87.
18. Sherman M. Hepatocellular carcinoma: epidemiology, risk factors, and screening. Semin Liver Dis 2005;25:143-54.
19. Wong GL, Chan HL, Chan HY, Tse PC, Tse YK, et al. Accuracy of risk scores for patients with chronic hepatitis B receiving entecavir treatment. Gastroenterology 2013;144:933-44.
20. Conti F, Buonfiglioli F, Scuteri A, Crespi C, Bolondi L, et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV related cirrhosis treated with direct-acting antivirals. J Hepatol 2016;65:727-33.
21. Bruix J, Sherman M; American association for the study of liver diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020-2.
22. Park JS, Yang JM, Min MK. Hepatitis C virus nonstructural protein NS4B transforms NIH3T3 cells in cooperation with the Ha-ras oncogene. Biochem Biophys Res Commun 2000;267:581-7.
23. Sakamuro D, Furukawa T, Takegami T. Hepatitis C virus nonstructural protein NS3 transforms NIH 3T3 cells. J Virol 1995;69:3893-6.
24. Lee DH, Lee JM. Primary malignant tumours in the non-cirrhotic liver. Eur J Radiol 2017;95:349-61.
25. Baffy G, Brunt EM, Caldwell SH. Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. J Hepatol 2012;56:1384-91.
26. Thompson SM, Garg I, Ehman EC, Sheedy SP, Bookwalter CA, et al. Non-alcoholic fatty liver disease-associated hepatocellular carcinoma: effect of hepatic steatosis on major hepatocellular carcinoma features at MRI. Br J Radiol 2018;91:20180345.
27. Ertle J, Dechêne A, Sowa J, Penndorf V, Herzer K, et al. Non-alcoholic fatty liver disease progressesto hepatocellular carcinoma in the absence of apparent cirrhosis. Int J Cancer 2011;128:2436-43.
28. Adami HO, Hsing AW, Mclaughlin JK, Trichopoulos D, Hacker D, et al. Alcoholism and liver cirrhosis in the etiology of primary liver cancer. Int J Cancer 1992;51:898-902.
29. London WT, McGlynn KA. Liver cancer. In: Schottenfeld D, Fraumeni Jr JF, editors. Cancer epidemiology and prevention. New York: Oxford University Press; 1996. pp. 772-93.
30. Burra P, Zanetto A, Germani G. Liver transplantation for alcoholic liver disease and hepatocellular carcinoma. Cancers (Basel) 2018;10:46.
31. Jiang HY, Chen J, Xia CC, Cao LK, Duan T, et al. Noninvasive imaging of hepatocellular carcinoma: from diagnosis to prognosis. World J Gastroenterol 2018;24:2348-62.
32. Ramakrishna G, Rastogi A, Trehanpati N, Sen B, Khosla R, et al. From cirrhosis to hepatocellular carcinoma: new molecular insights on inflammation and cellular senescence. Liver Cancer 2013;2:367-83.
33. Trehanpati N, Shrivastav S, Shivakumar B, Khosla R, Bhardwaj S, et al. Analysis of notch and TGF-β signaling expression in different stages of disease progression during hepatitis B virus infection. Clin Transl Gastroenterol 2012;3:e23.
34. Turlin B, Juguet F, Moirand R, Le Quilleuc D, Loréal O, et al. Increased liver iron stores in patients with hepatocellular carcinoma developed on a noncirrhotic liver. Hepatology 1995;22:446-50.
35. Ozakyol A. Global epidemiology of hepatocellular carcinoma (HCC epidemiology). J Gastrointest Canc 2017;48:238-40.
36. Liu CJ, Chen BF, Chen PJ, Lai MY, Huang WL, et al. Role of hepatitis B virus precore/core promoter mutations and serum viral load on noncirrhotic hepatocellular carcinoma: a case-control study. J Infect Dis 2006;194:594-9.
38. Zheng C, Zeng H, Lin H, Wang J, Feng X, et al. Serum microcystin levels positively linked with risk of hepatocellular carcinoma: a case-control study in southwest China. Hepatology 2017;66:1519-28.
39. Liu TC, Vachharajani N, Chapman WC, Brunt EM. Noncirrhotic hepatocellular carcinoma: derivation from hepatocellular adenoma? Clinicopathologic analysis. Mod Pathol 2014;27:420-32.
40. Farrell GC, Joshua DE, Uren RF, Baird PJ, Perkins KW, et al. Androgen-induced hepatoma. Lancet 1975;22:430-2.
41. Trevisani F, D’Intino PE, Caraceni P, Pizzo M, Stefanini GF, et al. Etiologic factors and clinical presentation of hepatocellular carcinoma. Differences between cirrhotic and noncirrhotic Italian patients. Cancer 1995;75:2220-32.
42. Lee Y, Park H, Lee H, Cho JY, Yoon YS, et al. The clinicopathological and prognostic significance of the gross classification of hepatocellular carcinoma. J Pathol Transl Med 2018;52:85-92.
43. Kojiro M. Pathology of hepatocellular carcinoma. Hoboken: Wiley; 2009. pp. 1-184.
44. Craig JR, Peters RL, Edmondson HA, Omata M. Fibrolamellar carcinoma of the liver: a tumor of adolescents and young adults with distinctive clinico-pathologic features. Cancer 1980;46:372-9.
45. Houben KW, McCall JL. Liver transplantation for hepatocellular carcinoma in patients without underlying liver disease: a systematic review. Liver Transpl Surg 1999;5:91-5.
46. Lin CC, Yang HM. Fibrolamellar carcinoma: a concise review. Arch Pathol Lab Med 2018;142:1141-5.
47. Van Eyken P, Sciot R, Brock P, Casteels-Van Daele M, Ramaekers FC, et al. Abundant expression of cytokeratin 7 in fibrolamellar carcinoma of the liver. Histopathology 1990;17:101-7.
48. Cheuk-Lam Lo R. An update on the histological subtypes ofhepatocellular carcinoma. Hepatoma Res 2019;5:41.
49. International consensus group for hepatocellular neoplasia. Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. Hepatology 2009;49:658-64.
50. Agni RM. Diagnostic histopathology of hepatocellular carcinoma: a case-based review. Semin Diagn Pathol 2017;34:126-37.
51. Bosman FTCF, Hruban RH, Theise ND. World Health Organization classification oftumours: pathology and genetics of tumours of the digestive system. Lyon, France: IARC Press; 2010.
52. Torbenson MS. Morphologic Subtypes of hepatocellular carcinoma. Gastroenterol Clin North Am 2017;46:365-91.
53. Ang CS, Kelley RL, Choti MA, Cosgrove DP, Chou JF, et al. Clinicopathologic characteristics and survivaloutcomes of patients with fibrolamellar carcinoma: data from the fibrolamellar carcinoma consortium. Gastrointest Cancer Res 2013;6:3-9.
54. Fujii T, Zen Y, Harada K, Harada K, Niwa HN, Masuda S, et al. Participation of liver cancer stem/progenitor cells in tumorigenesis of scirrhous hepatocellular carcinoma-human and cell culture study. Hum Pathol 2008;39:1185-96.
55. Lee JH, Choi MS, Gwak GY, Gwak GY, Lee JH, et al. Clinicopathologic characteristics and long-term prognosis of scirrhous hepatocellular carcinoma. Dig Dis Sci 2012;57:1698-707.
56. Trojan J, Zangos S, Schnitzbauer AA. Diagnostics and treatment of hepatocellular carcinoma in 2016: standards and developments. Visc Med 2016;32:116-120.
57. Chang CH, Chau GY, Lui WY, Tsay SH, King KL, et al. Long-term results of hepatic resection for hepatocellular carcinoma originating from the noncirrhotic liver. Arch Surg 2004;139:320-5.
58. Paradis V, Zalinski S, Chelbi E, Guedj N, Degos F, et al. Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis. Hepatology 2009;49:851-9.
59. Calderaro J, Couchy G, Imbeaud S, Amaddeo G, Letouzéet E, et al. Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification. J Hepatol 2017;67:727-38.
60. Okuda K, Nakashima T, Kojiro M, Kondo Y, Wada K. Hepatocellular carcinoma without cirrhosis in Japanese patients. Gastroenterology 1989;97:140-6.
61. Shimada M, Rikimaru T, Sugimachi K, Hamatsu T, Yamashita Y, et al. The importance of hepatic resection for hepatocellular carcinoma originating from nonfibrotic liver. J AmColl Surg 2000;191:531-7.
62. Grando-Lemaire V, Guettier C, Chevret S, Beaugrand M, Trinchet JC. Hepatocellular carcinoma without cirrhosis in the West: epidemiological factors and histopathology of the non-tumorous liver. Groupe d’Etude et de Traitement du Carcinome Hépatocellulaire. J Hepatol 1999;31:508-13.
63. Bralet MP, Régimbeau JM, Pineau P, Dubois S, Loas G, et al. Hepatocellular carcinoma occurring in nonfibrotic liver: epidemiologic and histopathologic analysis of 80 French cases. Hepatology 2000;32:200-4.
64. van Meer S, van Erpecum KJ, Sprengers D, Coenraad MJ, Klümpen HJ, et al. Hepatocellular carcinoma in cirrhotic versus noncirrhotic livers: results from a large cohort in the Netherlands. Eur J Gastroenterol Hepatol 2016;28:352-9.
65. Pittman ME, Brunt EM. Anatomic pathology of hepatocellular carcinoma: histopathology using classic and new diagnostic tools. Clin Liver Dis 2015;19:239-59.
66. Evason KJ, Grenert JP, Ferrell LD, Kakar S. Atypical hepatocellular adenoma-like neoplasms with β-catenin activation show cytogenetic alterations similar to well-differentiated hepatocellular carcinomas. Hum Pathol 2013;44:750-8.
67. Dokmak S, Paradis V, Vilgrain V, Sauvanet A, Farges O, et al. A single-center surgical experience of 122 patients with single and multiple hepatocellular adenomas. Gastroenterology 2009;137:1698-705.
68. Bioulac-Sage P, Laumonier H, Couchy G, Bail BL, Cunha A, et al. Hepatocellular adenoma management and phenotypic classification: the Bordeaux experience. Hepatology 2009;50:481-9.
69. Deneve JL, Pawlik TM, Cunningham S, Clary B, Reddy S, et al. Liver cell adenoma: a multicenter analysis of risk factors for rupture and malignancy. Ann Surg Oncol 2009;16:640-8.
70. Roncalli M, Sciarra A, Tommaso LD. Benign hepatocellular nodules of healthy liver: Focal nodular hyperplasia and hepatocellular adenoma. Clin Mol Hepatol 2016;22:199-211.
71. Libbrecht L, Cassiman D, Verslype C, Maleux G, Van Hees D, et al. Clinicopathological features of focal nodular hyperplasia-like nodules in 130 cirrhotic explant livers. Am J Gastroenterol 2006;101:2341-6.
72. Bioulac-Sage P, Laumonier H, Rullier A, Cubel G, Laurent C, et al. Over-expression of glutamine synthetase in focal nodular hyperplasia: a novel easy diagnostic tool in surgical pathology. Liver Int 2009;29:459-65.
73. Nakanuma Y, Sripa B, Vatanasapt B, Leong A, Ponchon T, et al. Intrahepatic cholangiocarcinoma. In: Hamilton SR, Aaltonen LA, editors. WHO Classification of Tumors, Pathology and Genetics Tumors of the Digestive System. Lyon: IARC Press; 2000. pp. 173-80.
75. El-Serag HB, Davila JA. Is fibrolamellar carcinoma different from hepatocellular carcinoma? A US population-based study. Hepatology 2004;39:798-803.
76. Ward SC, Huang J, Tickoo SK, Thung SN, Ladanyi M, et al. Fibrolamellar carcinoma of the liver exhibits immunohistochemical evidence of both hepatocyte and bile duct differentiation. Mod Pathol 2010;23:1180-90.
77. Ross HM, Daniel HD, Vivekanandan P, Kannangai R, Yeh MM, et al. Fibrolamellar carcinomas are positive for CD68. Mod Pathol 2011;24:390-5.
78. Schlageter M, Terracciano LM, D’Angelo S, Sorrentino P. Histopathology of hepatocellular carcinoma. World J Gastroenterol 2014;20:15955-64.
79. Melato M, Laurino L, Mucli E, Valente M, Okuda K. Relationship between cirrhosis, liver cancer, and hepatic metastases. An autopsy study. Cancer 1989;64:455-9.
80. Zucman-Rossi J, Villanueva A, Nault JC, Llovet JM. Genetic landscape and biomarkers of hepatocellular carcinoma. Gastroenterology 2015;149:1226-39.e4.
81. Tretiakova MS, Shabani-Rad MT, Guggisberg K, Hart J, Andera RA, et al. Genomic and immunophenotypical differences between hepatocellular carcinoma with and without cirrhosis. Histopathology 2010;56:683-93.
82. Tannapfel A, Wittekind C. Genes involved in hepatocellular carcinoma: deregulation in cell cycling and apoptosis. Virchows Arch 2002;440:345-52.
83. Sanyal AJ, Yoon SK, Lencioni R. The etiology of hepatocellular carcinoma and consequences for treatment. Oncologist 2010;15 Suppl 4:14-22.
84. Herzer K, Hofmann TG, Teufel A, Schimanski CC, Moehler M, et al. IFN-alpha-induced apoptosis in hepatocellular carcinoma involves promyelocytic leukemia protein and TRAIL independently of p53. Cancer Res 2009;69:855-62.
85. Mei Y, You Y, Xia J, Gong JP, Wang YB. Identifying differentially expressed microRNAs between cirrhotic and non-cirrhotic hepatocellular carcinoma and exploring their functions using bioinformatic analysis. Cell Physiol Biochem 2018;48:1443-56.
86. Zhang Y, Li T, Qiu Y, Zhang T, Guo P, et al. Serum microRNA panel for early diagnosis of the onset of hepatocellular carcinoma. Medicine (Baltimore) 2017;96:e5642.
87. Koh YS, Kim JH, Cai H, Li LH, Kim HS, et al. Dysregulated microRNAs in non-cirrhotic hepatocellular carcinoma. Genes Genom 2013;35:759-65.
88. Chiappini F, Gross-Goupil M, Saffroy R, Azoulay D, Emile JF, et al. Microsatellite instability mutator phenotype in hepatocellular carcinoma in non-alcoholic and non-virally infected normal livers. Carcinogenesis 2004;25:541-7.
89. Togni R, Bagla N, Muiesan P, Miquel R, O'Grady J, et al. Microsatellite instability in hepatocellularcarcinoma in non-cirrhotic liver in patients older than 60 years. Hepatol Res 2009;39:266-73.
90. Zeng W, Gouw AS, van den Heuvel MC, Molema G, Poppema S, et al. Hepatocellular carcinomas in cirrhotic and noncirrhotic human livers share angiogenic characteristics. Ann Surg Oncol 2010;17:1564-71.
91. Kakar S, Chen X, Ho C, Burgart LJ, Sahai V, et al. Chromosomal changes in fibrolamellar hepatocellular carcinoma detected by array comparative genomic hybridization. Mod Pathol 2009;22:134-41.
92. Grohmann M, Wiede F, Dodd GT, Gurzov EN, Ooi GJ, et al. Obesity drives STAT-1-dependent NASH and STAT-3-dependent HCC. Cell 2018;175:1289-306.e20.
93. Takakura K, Oikawa T, Nakano M, Saeki C, Torisu Y, et al. Recent insights into the multiple pathways driving non-alcoholic steatohepatitis-derived hepatocellular carcinoma. Front Oncol 2019;9:762.
94. Cazanave SC, Mott JL, Elmi NA, Bronk SF, Werneburg NW, et al. JNK1-dependent PUMA expression contributes to hepatocyte lipoapoptosis. J Biol Chem 2009;284:26591-602.
95. Shanbhogue AK, Prasad SR, Takahashi N, Vikram R, Sahani DV. Recent advances in cytogenetics and molecular biology of adult hepatocellular tumors: implications for imaging and management. Radiology 2011;258:673-93.
96. Schulze K, Imbeaud S, Letouze E, Alexandrov LB, Calderaro J, et al. Exome sequencing of hepatocellular carcinoma identifies new mutations signatures and potential therapeutic targets. Nat Genet 2015;47:505-11.
97. Ziol M, Pote N, Amaddeo G, Laurent A, Nault JC, et al. Macrotrabecular-massive hepatocellular carcinoma: a distinctive histological subtype with clinical relevance. Hepatology 2018;68:103-12.
98. Jeon Y, Benedict M, Taddei T, Jain D, Zhang X. Macrotrabecular hepatocellular carcinoma: an aggressive subtype of hepatocellular carcinoma. Am J Surg Pathol 2019;43:943-8.
99. Boyault S, Rickman DS, de Reynies A, Balabaud C, Rebouissou S, et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology 2007;45:42-52.
100. Zhang L, Yang N, Park JW, Katsaros D, Fracchioli S, et al. Tumor-derived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer. Cancer Res 2003;63:3403-12.
101. Salomao M, Yu WM, Brown RS Jr, Emond JC, Lefkowitch JH. Steatohepatitic hepatocellular carcinoma (SH-HCC): a distinctive histological variant of HCC in hepatitis C virus-related cirrhosis with associated NAFLD/NASH. Am J Surg Pathol 2010;34:1630-6.
102. Tan PS, Nakagawa S, Goossens N, Venkatesh A, Huang T, et al. Clinicopathological indices to predict hepatocellular carcinoma molecular classification. Liver Int 2016;36:108-18.
103. Ando S, Shibahara J, Hayashi A, Fukayama M. β-catenin alteration is rare in hepatocellular carcinoma with steatohepatitic features: immunohistochemical and mutational study. Virchows Arch 2015;467:535-42.
104. Labgaa I, Stueck A, Ward SC. Lymphoepithelioma-like carcinoma in liver. Am J Pathol 2017;187:1438-44.
105. Chan AW, Zhang Z, Chong CC, Tin EK, Chow C, et al. Genomic landscape of lymphoepithelioma-like hepatocellular carcinoma. J Pathol 2019;249:166-72.
106. Han Y, Wu Y, Yang C, Huang J, Guo Y, et al. Dynamic and specific immune responses against multiple tumor antigens were elicited in patients with hepatocellular carcinoma after cell-based immunotherapy. J Transl Med 2017;15:64.
107. Seok JY, Na DC, Woo HG, Roncalli M, Kwon SM, et al. A fibrous stromal component in hepatocellular carcinoma reveals a cholangiocarcinoma-like gene expression trait and epithelial-mesenchymal transition. Hepatology 2012;55:1776-86.
108. Honeyman JN, Simon EP, Robine N, Chiaroni-Clarke R, Darcy DG, et al. Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma. Science 2014;343:1010-4.
109. Riggle KM, Turnham R, Scott JD, Yeung RS, Riehle KJ. Fibrolamellar hepatocellular carcinoma: mechanistic distinction from adult hepatocellular carcinoma. Pediatr Blood Cancer 2016;63:1163-7.
110. Kastenhuber ER, Lalazar G, Houlihan SL, Tschaharganeh DF, Baslan T, et al. DNAJB1-PRKACA fusion kinase interacts with beta-catenin and the liver regenerative response to drive fibrolamellar hepatocellular carcinoma. Proc Natl Acad Sci U S A 2017;114:13076-84.
111. Wilkens L, Bredt M, Flemming P, Kubicka S, Klempnauer J, et al. Cytogenetic aberrations in primary and recurrent fibrolamellar hepatocellular carcinoma detected by comparative genomic hybridization. Am J Clin Pathol 2000;114:867-74.
112. Joseph NM, Tsokos CG, Umetsu SE, Shain AH, Kelley RK, et al. Genomic profiling of combined hepatocellular-cholangiocarcinoma reveals similar genetics to hepatocellular carcinoma. J Pathol 2019;248:164-78.
113. Seehawer M, Heinzmann F, D’Artista L, Harbig J, Roux PF, et al. Necroptosis microenvironment directs lineage commitment in liver cancer. Nature 2018;562:69-75.
114. Cancer Genome Atlas Research Network. Comprehensive and inte-grative genomic characterization of hepatocellular carcinoma. Cell 2017;169:1327-41.
